Patents by Inventor Maximillian ROGERS

Maximillian ROGERS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS RELATING TO INHIBITING CARDIOVASCULAR CALCIFICATION VIA ANNEXIN A1
    Publication number: 20210353721
    Abstract: The technology described herein is directed methods of treating an extracellular vesicle (EV)-associated disease or vascular calcification in subject by administration of an agent that reduces the levels or activity of Annexin A1 (ANXA1).
    Type: Application
    Filed: August 7, 2019
    Publication date: November 18, 2021
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Elena AIKAWA, Maximillian ROGERS, Masanori AIKAWA
  • Modulation of PCSK9 and LDLR through DRP1 inhibition
    Patent number: 10960020
    Abstract: Provided herein are methods for reducing levels of blood cholesterol, low-density lipoprotein (LDL), and/or the treatment of diseases associated with high cholesterol, hyperlipidemia, dyslipidemia, or high levels of low-density lipoprotein (LDL), wherein the methods comprise administering a DRP1 inhibitor to a subject in need thereof. In certain embodiments, the subject is selected for treatment as described herein when the subject exhibits intolerance to conventional statin therapy. Also contemplated herein are the use of DRP1 inhibitors in the treatment of cancer and inflammatory disease.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: March 30, 2021
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Elena Aikawa, Maximillian Rogers, Masanori Aikawa
  • MODULATION OF PCSK9 AND LDLR THROUGH DRP1 INHIBITION
    Publication number: 20190209603
    Abstract: Provided herein are methods for reducing levels of blood cholesterol, low-density lipoprotein (LDL), and/or the treatment of diseases associated with high cholesterol, hyperlipidemia, dyslipidemia, or high levels of low-density lipoprotein (LDL), wherein the methods comprise administering a DRP1 inhibitor to a subject in need thereof. In certain embodiments, the subject is selected for treatment as described herein when the subject exhibits intolerance to conventional statin therapy. Also contemplated herein are the use of DRP1 inhibitors in the treatment of cancer and inflammatory disease.
    Type: Application
    Filed: September 12, 2017
    Publication date: July 11, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Elena AIKAWA, Maximillian ROGERS, Masanori AIKAWA
  • Methods for treating Niemann-Pick type C disease
    Patent number: 9206425
    Abstract: The present invention includes methods for treating Niemann-Pick Type C disease through administration of inhibitors of acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1). ACAT inhibitors are used to treat symptoms of Niemann-Pick Type C disease and prolong survival of patients with the disease, either alone or in combination with other treatments.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: December 8, 2015
    Assignee: Trustees of Dartmouth College
    Inventors: Ta-Yuan Chang, Catherine C. Y. Chang, Maximillian A. Rogers
  • Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
    Patent number: 9149492
    Abstract: The present invention features methods for stimulating clearance of amyloid beta in microglia, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the expression or activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: October 6, 2015
    Assignee: Trustees of Dartmouth College
    Inventors: Ta-Yuan Chang, Catherine C. Y. Chang, Yohei Shibuya, Elena Bryleva, Stephanie Murphy, Maximillian A. Rogers
  • Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease
    Patent number: 8802646
    Abstract: The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: August 12, 2014
    Assignee: Trustees of Dartmouth College
    Inventors: Ta-Yuan Chang, Catherine C. Y. Chang, Elena Bryleva, Stephanie Murphy, Maximillian A. Rogers
  • METHODS FOR TREATING NIEMANN-PICK TYPE C DISEASE
    Publication number: 20140220114
    Abstract: The present invention includes methods for treating Niemann-Pick Type C disease through administration of inhibitors of acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1). ACAT inhibitors are used to treat symptoms of Niemann-Pick Type C disease and prolong survival of patients with the disease, either alone or in combination with other treatments.
    Type: Application
    Filed: July 24, 2012
    Publication date: August 7, 2014
    Applicant: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Ta-Yuan Chang, Catherine C.Y. Chang, Maximillian A. Rogers
  • METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20140044757
    Abstract: The present invention features methods for stimulating clearance of amyloid beta in microglia, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the expression or activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
    Type: Application
    Filed: September 11, 2013
    Publication date: February 13, 2014
    Applicant: Trustees of Dartmouth College
    Inventors: Ta-Yuan Chang, Catherine C.Y. Chang, Yohei Shibuya, Elena Bryleva, Stephanie Murphy, Maximillian A. Rogers